PL3600281T3 - Terapia skojarzona w leczeniu i profilaktyce nowotworów - Google Patents

Terapia skojarzona w leczeniu i profilaktyce nowotworów

Info

Publication number
PL3600281T3
PL3600281T3 PL18770812.8T PL18770812T PL3600281T3 PL 3600281 T3 PL3600281 T3 PL 3600281T3 PL 18770812 T PL18770812 T PL 18770812T PL 3600281 T3 PL3600281 T3 PL 3600281T3
Authority
PL
Poland
Prior art keywords
tumours
prevention
treatment
combination therapy
therapy
Prior art date
Application number
PL18770812.8T
Other languages
English (en)
Polish (pl)
Inventor
Paul Warren Reddell
Jason Kingsley CULLEN
Glen Mathew BOYLE
Peter Gordon Parsons
Victoria Anne Gordon
Original Assignee
QBiotics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901027A external-priority patent/AU2017901027A0/en
Application filed by QBiotics Pty Ltd filed Critical QBiotics Pty Ltd
Publication of PL3600281T3 publication Critical patent/PL3600281T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL18770812.8T 2017-03-23 2018-03-23 Terapia skojarzona w leczeniu i profilaktyce nowotworów PL3600281T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017901027A AU2017901027A0 (en) 2017-03-23 Combination Therapy
PCT/AU2018/050277 WO2018170559A1 (en) 2017-03-23 2018-03-23 Combination therapy for the treatment or prevention of tumours

Publications (1)

Publication Number Publication Date
PL3600281T3 true PL3600281T3 (pl) 2023-09-11

Family

ID=63583892

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18770812.8T PL3600281T3 (pl) 2017-03-23 2018-03-23 Terapia skojarzona w leczeniu i profilaktyce nowotworów

Country Status (27)

Country Link
US (1) US11213506B2 (sr)
EP (1) EP3600281B1 (sr)
JP (1) JP6905075B2 (sr)
KR (1) KR102228055B1 (sr)
CN (1) CN110461324A (sr)
AU (1) AU2018238202C1 (sr)
CA (1) CA3056685C (sr)
DK (1) DK3600281T3 (sr)
EA (1) EA201992220A1 (sr)
ES (1) ES2953575T3 (sr)
FI (1) FI3600281T3 (sr)
HR (1) HRP20230936T1 (sr)
HU (1) HUE063299T2 (sr)
IL (1) IL269522B2 (sr)
LT (1) LT3600281T (sr)
MX (1) MX391826B (sr)
MY (1) MY197427A (sr)
PH (1) PH12019502132A1 (sr)
PL (1) PL3600281T3 (sr)
PT (1) PT3600281T (sr)
RS (1) RS64472B1 (sr)
SG (1) SG11201907891XA (sr)
SI (1) SI3600281T1 (sr)
SM (1) SMT202300272T1 (sr)
UA (1) UA125614C2 (sr)
WO (1) WO2018170559A1 (sr)
ZA (1) ZA201906001B (sr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1971588T3 (da) * 2005-12-23 2012-10-22 Qbiotics Ltd Tiglien-3-onderivater
KR102160389B1 (ko) 2013-08-05 2020-09-28 트위스트 바이오사이언스 코포레이션 드 노보 합성된 유전자 라이브러리
CA2975852A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
WO2016172377A1 (en) 2015-04-21 2016-10-27 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
KR20180050411A (ko) 2015-09-18 2018-05-14 트위스트 바이오사이언스 코포레이션 올리고핵산 변이체 라이브러리 및 그의 합성
WO2017053450A1 (en) 2015-09-22 2017-03-30 Twist Bioscience Corporation Flexible substrates for nucleic acid synthesis
EP4664304A3 (en) 2016-09-21 2026-01-21 Atlas Data Storage, Inc. Nucleic acid based data storage
WO2018156792A1 (en) 2017-02-22 2018-08-30 Twist Bioscience Corporation Nucleic acid based data storage
IL271205B2 (en) 2017-06-12 2025-02-01 Twist Bioscience Corp Methods for assembling continuous nucleic acids
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
CN111566125A (zh) 2017-09-11 2020-08-21 特韦斯特生物科学公司 Gpcr结合蛋白及其合成
CN111565834B (zh) 2017-10-20 2022-08-26 特韦斯特生物科学公司 用于多核苷酸合成的加热的纳米孔
IL312616B2 (en) 2018-01-04 2025-08-01 Twist Bioscience Corp Dna-based digital information storage
EP3814497A4 (en) 2018-05-18 2022-03-02 Twist Bioscience Corporation POLYNUCLEOTIDES, REAGENTS AND METHODS FOR NUCLEIC ACID HYBRIDIZATION
EP3902816A4 (en) 2018-12-26 2022-09-14 Twist Bioscience Corporation HIGH-PRECISION DE NOVO POLYNUCLEOTIDE SYNTHESIS
CA3131689A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for glp1 receptor
KR20210144698A (ko) 2019-02-26 2021-11-30 트위스트 바이오사이언스 코포레이션 항체 최적화를 위한 변이 핵산 라이브러리
PL3952858T3 (pl) * 2019-04-12 2026-03-30 QBiotics Pty Ltd Sposób leczenia guzów
BR112021024716A2 (pt) * 2019-06-19 2022-02-08 QBiotics Pty Ltd Ruptura de biofilme
EP3987019A4 (en) 2019-06-21 2023-04-19 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
CN115023440B (zh) 2019-09-23 2025-09-12 特韦斯特生物科学公司 结合CD3ε的抗体
US12091777B2 (en) 2019-09-23 2024-09-17 Twist Bioscience Corporation Variant nucleic acid libraries for CRTH2
AU2020400030B2 (en) 2019-12-09 2026-05-21 Twist Bioscience Corporation Variant nucleic acid libraries for adenosine receptors
WO2022159620A1 (en) 2021-01-21 2022-07-28 Twist Bioscience Corporation Methods and compositions relating to adenosine receptors
KR102774792B1 (ko) 2021-05-06 2025-03-05 한국과학기술연구원 가시광선에 의해 활성화되는 항암 면역치료용 나노입자 및 이의 용도
CN118451065A (zh) * 2021-12-21 2024-08-06 Q生物股份有限公司 结晶中间体
JP2025505797A (ja) * 2022-02-17 2025-02-28 キューバイオティクス プロプライアタリー リミティド 併用療法
EP4638430A4 (en) * 2022-12-21 2026-07-01 QBiotics Pty Ltd CRYSTALLINE FORMS AND THEIR PRODUCTION PROCESSES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007009055A2 (en) * 2005-07-13 2007-01-18 Salvia Sciences, Inc. Ester prodrugs of prostratin and related phorbol compounds
DK1971588T3 (da) * 2005-12-23 2012-10-22 Qbiotics Ltd Tiglien-3-onderivater
PT2986615T (pt) * 2013-04-18 2019-03-22 Qbiotics Ltd Métodos e composições para a cicatrização de feridas
JP6501413B2 (ja) * 2014-03-07 2019-04-17 国立大学法人京都大学 細胞培養用組成物
ES2833425T3 (es) 2014-07-16 2021-06-15 Roussy Inst Gustave Combinación de virus oncolítico con moduladores de punto de control inmunitario
CA2964155A1 (en) 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors
CN104926758A (zh) * 2015-05-22 2015-09-23 南京泽朗医药科技有限公司 斑籽素的制备方法及其在抗白血病药物中的应用
AR105592A1 (es) * 2015-08-03 2017-10-18 Quadriga Biosciences Inc b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS

Also Published As

Publication number Publication date
PH12019502132A1 (en) 2020-07-06
US11213506B2 (en) 2022-01-04
JP6905075B2 (ja) 2021-07-21
AU2018238202B2 (en) 2024-03-28
KR102228055B1 (ko) 2021-03-16
SI3600281T1 (sl) 2023-10-30
AU2018238202A8 (en) 2024-03-28
SG11201907891XA (en) 2019-09-27
US20200030279A1 (en) 2020-01-30
PT3600281T (pt) 2023-09-04
EA201992220A1 (ru) 2020-02-11
NZ756754A (en) 2024-02-23
MX391826B (es) 2025-03-21
IL269522A (sr) 2019-11-28
RS64472B1 (sr) 2023-09-29
WO2018170559A1 (en) 2018-09-27
ZA201906001B (en) 2023-12-20
LT3600281T (lt) 2023-09-11
MY197427A (en) 2023-06-16
DK3600281T3 (da) 2023-08-14
IL269522B1 (en) 2024-01-01
SMT202300272T1 (it) 2023-09-06
HUE063299T2 (hu) 2024-01-28
UA125614C2 (uk) 2022-05-04
ES2953575T3 (es) 2023-11-14
BR112019019748A2 (pt) 2020-04-14
EP3600281A4 (en) 2020-03-18
KR20190126431A (ko) 2019-11-11
AU2018238202A1 (en) 2019-09-19
CA3056685A1 (en) 2018-09-27
AU2018238202C1 (en) 2025-06-05
JP2020511512A (ja) 2020-04-16
HRP20230936T1 (hr) 2023-11-24
CA3056685C (en) 2024-01-16
MX2019011221A (es) 2019-11-01
EP3600281B1 (en) 2023-05-31
FI3600281T3 (fi) 2023-08-24
IL269522B2 (en) 2024-05-01
CN110461324A (zh) 2019-11-15
EP3600281A1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
PT3600281T (pt) Terapia combinada para o tratamento ou prevenção de tumores
IL291844B1 (en) smc combined therapy for cancer treatment
IL289650A (en) Azolopyrimidine for the treatment of cancer-related disorders
IL290149A (en) Combined treatment for cancer
IL267795A (en) Combined treatment for cancer
IL276398A (en) Combined treatment for mastocytosis
IL256224B (en) Combined therapy for cancer treatment
IL258002A (en) Cenicriviroc combination therapy for the treatment of fibrosis
IL258521A (en) Combination of treatments for cancer treatment
IL280337A (en) LAG-3 combination therapy for cancer treatment
IL272097A (en) Compounds for the prevention and treatment of medical disorders and their uses
SG11202103141YA (en) Combination therapy for the treatment of cancer
IL272560A (en) Combined treatment
IL266993A (en) Combined therapy for cancer treatment
IL284162A (en) Integrated healing for cancer treatment
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
IL273835A (en) Combined product for cancer treatment
IL281782A (en) Drug combination for cancer treatment
IL255169A0 (en) Treatment combination of an anti-pogatactic factor and an immunotherapy factor and compounds for the treatment of cancer
IL253642A0 (en) Combined treatment for cancer
HK40009465A (en) Combination therapy for the treatment of cancer
GB201704474D0 (en) Combination therapy for treatment of cancer
GB201801502D0 (en) Combination therapy for treating or preventing cancer
GB201700502D0 (en) Treatment of tumours of the central nervous system